Company: SUPN
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001356576-25-000071
Chunk: 218

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 218
---
 to leases is as follows (dollars in thousands):Nine Months EndedSeptember 30,20252024(unaudited)Cash paid for operating leases$14,415 $13,224 Lease assets obtained for new operating leases9,941 3,547 Lease obtained from Sage Acquisition As part of the Sage Acquisition, the Company acquired a lease for office space located in a multi-tenant building located in Cambridge, Massachusetts and classified this as an operating lease. Sages's office space lease term continues through February 28, 2030. See Note 3, Sage Acquisition, for the further discussion on the acquired lease asset and assumed lease liability.

14. Segment Reporting 

The Company operates in one operating segment and therefore has only one reportable segment. The Company derives revenue primarily from sales of its commercial products in the U.S.The Company's chief operating decision maker (CODM) is the chief executive officer. The Company manages the business activities on a consolidated basis. The CODM assesses performance of the Company, decides how to allocate resources based on net earnings (loss), which is reported in the condensed consolidated statement of earnings (loss) as net earnings (loss), and allocates resources on a consolidated basis. The CODM uses net earnings (loss) to decide whether to reinvest profits into the Company's current products or into other research and development initiatives for the Company's product candidates. Net earnings (loss) is also used to monitor budget versus actual results.The measure of the reportable segment assets is reported on the balance sheet as total assets. 

30

The following table shows the segment revenue, significant segment expenses and net earnings (loss) (dollars in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024(unaudited)(unaudited)Total revenues$192,103 $175,689 $507,380 $487,658 Less: Significant segment expenses:Cost of goods sold18,965 17,583 51,555 51,808 Selling expenses58,386 38,082 145,398 116,190 Marketing expenses18,672 16,247 60,068 56,510 General and administrative expenses(a)33,114 15,424 86,833 69,473 Acquisition-related expenses(b)69,506 — 70,874 — Research and development expensesExternal development program expenses:ONAPGO352 71